Map.Ax
MAP.AX operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Business. MAP.AX operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MAP.AX operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
MAP.AX has a liquidity position that is characterized by a current ratio of 1.87, indicating that the company has sufficient current assets to cover its current liabilities. However, the company's free cash flow is negative at -13,407,660 AUD, which suggests that it is not generating enough cash from operations to fund its capital expenditures and other operational needs.
In terms of profitability, MAP.AX is currently experiencing a return on equity of -0.4598 and a return on assets of -0.3149, both of which are negative and indicate that the company is not generating a return on its equity or assets. These figures are below the industry norms and suggest that the company is underperforming in terms of profitability.
The company's revenue is concentrated in the healthcare services and equipment segment, with no specific geographic breakdown provided in the available data. This concentration may pose a risk if the demand for healthcare services and equipment were to decline.
MAP.AX's growth trajectory is uncertain, as the company reported a net loss of 14,939,470 AUD and an operating loss of 17,648,000 AUD. The negative operating and net income figures indicate that the company is not currently profitable and may face challenges in achieving sustainable growth.
The risk assessment for MAP.AX indicates a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations.
Recent events related to MAP.AX include analyst estimates that suggest a mean price target of 0.20 AUD and a median price target of 0.20 AUD, with a mean recommendation of 1.50, indicating a generally positive outlook from analysts.
- MAP.AX is currently experiencing a negative return on equity and assets, indicating poor profitability.
- The company's liquidity position is moderate, with a current ratio of 1.87, but it is not generating positive free cash flow.
- The company's revenue is concentrated in the healthcare services and equipment segment, with no specific geographic breakdown.
- Analysts have a generally positive outlook on MAP.AX, with a mean price target of 0.20 AUD and a mean recommendation of 1.50.
- The company is not currently profitable, with a net loss and an operating loss reported.
- margin_outlook_rationale: The company's negative return on equity and assets suggests that its margins are currently unprofitable.
- rd_outlook_rationale: No specific information is provided regarding the company's research and development outlook.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,02 |
| Revenue | —no estimate | —no estimate | 18,3M AUD |
| Operating income | —no estimate | —no estimate | -15,1M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MAP.AX Market data — financials · 2026-05-28
- Microba Life Sciences Ltd Market data — analyst estimates · 2026-05-28